para- aminomethylbenzoic acid

Structural formula
General
Surname	Para-aminomethylbenzoic acid
other names	4- (aminomethyl) benzoic acid ( IUPAC ) ; p-aminomethylbenzoic acid; PAMBA;
Molecular formula	C 8 H 9 NO 2
External identifiers / databases
EC number	200-297-9
ECHA InfoCard	100,000,271
PubChem	65526
Wikidata	Q695442
Drug information
ATC code	B02 AA03
Drug class	Fibrinolysis inhibitor
properties
Molar mass	151.16 g mol −1
Melting point	> 300 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 315-319-335
	P: 261-305 + 351 + 338
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

The para -Aminomethylbenzoesäure (trade name: Pamba (D), manufacturer: Takeda ) is the amino acid lysine structurally related substance ( analog ) and one of the ε-amino carboxylic acids . As a medicinal substance , it is used medicinally to promote hemostasis.

Para- aminomethylbenzoic acid belongs to the group of antifibrinolytics , which means that the substance inhibits the dissolution of clots ( fibrinolysis ).

effect

Para- aminomethylbenzoic acid inhibits the formation of active plasmin from plasminogen by attachment to the plasmin binding site for lysine . This suppresses the accumulation of plasmin on fibrin or fibrinogen and consequently the clot dissolution (fibrinolysis) is inhibited.

The mode of action is similar to that of the structurally similar ε-aminocarboxylic acid tranexamic acid .

The elimination half-life in the blood plasma is about one to two hours with an effect of four to six hours. Para- aminomethylbenzoic acid is largely excreted unchanged via the kidneys.

para- Aminomethylbenzoic acid is well absorbed and can be administered both parenterally and orally .

application

In medicine, para- aminomethylbenzoic acid is u. a. Used as an antidote for the treatment of hyperfibrinolysis , triggered by fibrinolytics , or in rare, congenital disorders in the production of fibrinolysis inhibitors.

Treatment with para- aminomethylbenzoic acid should be carried out under the supervision of a doctor experienced in the treatment of coagulation disorders and only if other therapeutic measures are not sufficient.

Individual evidence

↑ ^a ^b ^c data sheet 4- (aminomethyl) benzoic acid from Sigma-Aldrich , accessed on November 7, 2016 ( PDF ).
↑ K. Aktories, U. Förstermann, W. Forth: General and special pharmacology and toxicology. 9th edition, Elsevier, Urban & FischerVerlag, 2006, p. 547, ISBN 978-3-437-44490-6 .
↑ ^a ^b C.-J. Estler, H. Schmidt (Ed.): Pharmacology and Toxicology. 6th edition, Schattauer Verlag, 2007, pp. 547-547, ISBN 978-3-7945-2295-8 .
↑ technical information Gumbix, May 2005, professional information PAMBA May of 2005.

[sigma-1] ta sheet 4- (aminomethyl) benzoic acid from Sigma-Aldrich , accessed on November 7, 2016 ( PDF ).

[2] K. Aktories, U. Förstermann, W. Forth: General and special pharmacology and toxicology. 9th edition, Elsevier, Urban & FischerVerlag, 2006, p. 547, ISBN 978-3-437-44490-6 .

[estler-3] C.-J. Estler, H. Schmidt (Ed.): Pharmacology and Toxicology. 6th edition, Schattauer Verlag, 2007, pp. 547-547, ISBN 978-3-7945-2295-8 .

[fi-4] technical information Gumbix, May 2005, professional information PAMBA May of 2005.